Genentech, a member of the Roche Group , has announced the launch of its first Direct-to-Patient (DTP) program, designed to make its influenza treatment Xofluza® (baloxavir marboxil) more affordable and accessible for Americans. The initiative supports the broader goal of expanding access to essential medicines for patients who are uninsured, underinsured, or whose health plans do not cover Xofluza.
Xofluza is a single-dose oral antiviral medication used to treat influenza in patients aged five years and older, as well as for post-exposure prophylaxis in individuals who have been exposed to the flu.
“This new approach will allow for convenient, same-day delivery of our vital flu treatment in select U.S. markets,” said Ashley Magargee, Chief Executive Officer of Genentech. “Expanding our distribution for Xofluza will allow us to reach more patients where they are increasingly interested in seeking their medicines.”
Key Features of the Direct-to-Patient Program
Genentech has partnered with three major pharmacy providers—Alto Pharmacy Powered by Fuze Health, Amazon Pharmacy, and the Mark Cuban Cost Plus Drug Company, PBC—to deliver Xofluza directly to patients with a valid prescription.
Affordable Pricing: Eligible patients can access Xofluza for a new $50 cash pay option, which is approximately 70% lower than the list price, through Alto Pharmacy and Cost Plus Drugs.
Same-Day Home Delivery: Available in select U.S. markets via Alto Pharmacy Powered by Fuze Health and Amazon Pharmacy, enabling patients to receive medication quickly and conveniently.
Nationwide Delivery: Patients across the country can opt for home delivery by mail from any of the three pharmacy partners, including those using Xofluza as a prophylaxis treatment to prevent flu after exposure.
Addressing a Severe Flu Season
The U.S. Centers for Disease Control and Prevention (CDC) reported that the 2024–25 influenza season was among the most severe since 2017–18, with an estimated 47–82 million illnesses, 21–37 million medical visits, 610,000–1.3 million hospitalizations, and 27,000–130,000 deaths across all age groups.
Antivirals like Xofluza play a crucial role in treating and preventing severe outcomes from influenza, particularly in vulnerable populations.
Additional Affordability Programs
Genentech continues to offer financial support initiatives to ensure patients can access its medicines. The company has enhanced the Xofluza coupon program for this flu season:
Eligible patients pay as little as $35 for their prescription, with up to $70 in savings at most pharmacies.
The coupon is automatically applied for eligible orders at Alto Pharmacy Powered by Fuze Health and Amazon Pharmacy, ensuring a seamless purchasing experience.
Through this Direct-to-Patient initiative, Genentech aims to expand access, lower costs, and simplify delivery for patients seeking timely treatment during flu season.